We are proud to announce that we have been appointed as the official video makers for the 2020 Made in Sheffield Awards.

The Awards are held every two years and we produced the video to introduce the 2018 awards, which led the Insider Group, the organisation responsible for staging the Awards, to appoint us again in 2020.

The Made in Sheffield brand gives local companies the opportunity to celebrate their ongoing commitment to world class quality and excellence in manufacturing. More than 250 companies are licensed to use the Made in Sheffield logo.

The awards will offer manufacturers the opportunity to network, make new contacts and gain valuable insight. It is a chance to bring their national and international business contacts to see for themselves what the Sheffield City Region has to offer.

Our video will feature some of the winners from the last event in 2018 and their stories will act as an illustration of what makes manufacturers in the Sheffield City region so successful in a global market when they face stiff competition from other international companies.

This year seven awards will be given on the night, they are:

• Manufacturing Innovation Award
• Export Award
• Apprentice of the Year
• Manufacturing Apprenticeship / Training Programme
• Food & Drink Award
• Manufacturer of the Year (under £25m)
• Made in Sheffield Award

Our videos are embedded in Volition press releases

Nasdaq-quoted company Volition RX, one of our key clients, has started to use our videos as an integral part of their media releases.

The latest (pictured right) included an interview with Volition CEO, Cameron Reynolds, talking about Volition’s latest acquisition and also covering a series of other recent milestones and a look ahead to their activities in 2020.

The announcement gave details about the closing of the acquisition of the epigenetic reagent company Octamer GmbH (“Octamer”) by its subsidiary Belgian Volition SPRL for approximately $725,000, consisting of cash and shares of restricted common stock of Volition. This strategic acquisition helps secure the supply of one of the key components of Volition’s Nu.Q(TM) tests, the recombinant nucleosome used as the calibrant.

Volition also announced the receipt of additional non-dilutive funding in the form of a $550,000 (Euro 500,000) unsecured loan from Namur Invest to assist with the Octamer acquisition. This takes the total non-dilutive funding provided by the Namur Regional Government and associated agencies to over $7 million to-date.

Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer. Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases.